S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
NYSE:DGX

Quest Diagnostics - DGX Stock Forecast, Price & News

$140.02
+0.64 (+0.46%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$139.45
$140.92
50-Day Range
$127.07
$145.39
52-Week Range
$125.33
$174.16
Volume
519,591 shs
Average Volume
1.11 million shs
Market Capitalization
$16.33 billion
P/E Ratio
11.65
Dividend Yield
1.89%
Price Target
$150.33

Quest Diagnostics MarketRank™ Forecast

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
7.4% Upside
$150.33 Price Target
Short Interest
Bearish
3.99% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.43mentions of Quest Diagnostics in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$47.19 M Sold Last Quarter
Proj. Earnings Growth
-14.04%
From $9.69 to $8.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

401st out of 1,293 stocks

Medical Laboratories Industry

16th out of 31 stocks

DGX stock logo

About Quest Diagnostics (NYSE:DGX) Stock

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Quest Diagnostics Stock Up 1.0 %

Shares of NYSE:DGX opened at $139.38 on Monday. Quest Diagnostics has a 1 year low of $125.33 and a 1 year high of $174.16. The company has a market cap of $16.25 billion, a PE ratio of 11.60 and a beta of 1.00. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.54 and a quick ratio of 1.42. The stock's 50-day moving average is $135.08 and its 200 day moving average is $136.15.

Quest Diagnostics (NYSE:DGX - Get Rating) last posted its earnings results on Thursday, July 21st. The medical research company reported $2.36 earnings per share for the quarter, topping analysts' consensus estimates of $2.26 by $0.10. Quest Diagnostics had a return on equity of 24.62% and a net margin of 14.02%. The firm had revenue of $2.45 billion for the quarter, compared to the consensus estimate of $2.34 billion. During the same quarter in the prior year, the business earned $3.18 EPS. The business's revenue for the quarter was down 3.8% on a year-over-year basis. Sell-side analysts anticipate that Quest Diagnostics will post 9.69 EPS for the current year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 20th. Shareholders of record on Wednesday, July 6th were issued a dividend of $0.66 per share. The ex-dividend date was Tuesday, July 5th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.89%. Quest Diagnostics's dividend payout ratio (DPR) is 21.96%.

Analyst Ratings Changes

A number of research firms have recently weighed in on DGX. UBS Group boosted their target price on Quest Diagnostics from $139.00 to $150.00 in a research note on Sunday, April 24th. Wells Fargo & Company boosted their target price on Quest Diagnostics from $145.00 to $150.00 and gave the company an "equal weight" rating in a research note on Monday, April 25th. Bank of America lowered their target price on Quest Diagnostics from $166.00 to $163.00 and set a "buy" rating for the company in a research note on Friday, April 22nd. Finally, StockNews.com raised Quest Diagnostics from a "hold" rating to a "buy" rating in a research note on Thursday, July 7th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $150.33.

Insiders Place Their Bets

In other Quest Diagnostics news, CEO Stephen H. Rusckowski sold 282,408 shares of the company's stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $140.12, for a total transaction of $39,571,008.96. Following the transaction, the chief executive officer now owns 334,833 shares in the company, valued at approximately $46,916,799.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Stephen H. Rusckowski sold 282,408 shares of the company's stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $140.12, for a total value of $39,571,008.96. Following the sale, the chief executive officer now owns 334,833 shares in the company, valued at approximately $46,916,799.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael E. Prevoznik sold 50,604 shares of the company's stock in a transaction that occurred on Tuesday, May 17th. The stock was sold at an average price of $139.97, for a total value of $7,083,041.88. Following the completion of the sale, the senior vice president now owns 39,224 shares in the company, valued at approximately $5,490,183.28. The disclosure for this sale can be found here. In the last quarter, insiders have sold 337,012 shares of company stock worth $47,193,071. Company insiders own 1.70% of the company's stock.

Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

DGX Stock News Headlines

4 Analysts Have This to Say About Quest Diagnostics
Quest Diagnostics Raises 2022 Guidance
Quest Diagnostics Q2 Profit Decreases, but beats estimates
See More Headlines
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

DGX Company Calendar

Ex-Dividend for 7/20 Dividend
7/05/2022
Dividend Payable
7/20/2022
Last Earnings
7/21/2022
Today
8/08/2022
Next Earnings (Estimated)
10/20/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
74834L10
Employees
49,000
Year Founded
1967

Price Target and Rating

Average Stock Price Forecast
$150.33
High Stock Price Forecast
$170.00
Low Stock Price Forecast
$129.00
Forecasted Upside/Downside
+7.4%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$2.00 billion
Pretax Margin
18.25%

Debt

Sales & Book Value

Annual Sales
$10.79 billion
Cash Flow
$18.30 per share
Book Value
$52.85 per share

Miscellaneous

Free Float
114,624,000
Market Cap
$16.33 billion
Optionable
Optionable
Beta
1.00

Social Links















DGX Stock - Frequently Asked Questions

Should I buy or sell Quest Diagnostics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View DGX analyst ratings
or view top-rated stocks.

What is Quest Diagnostics' stock price forecast for 2022?

10 Wall Street analysts have issued 12 month target prices for Quest Diagnostics' stock. Their DGX stock forecasts range from $129.00 to $170.00. On average, they predict the company's stock price to reach $150.33 in the next twelve months. This suggests a possible upside of 7.1% from the stock's current price.
View analysts price targets for DGX
or view top-rated stocks among Wall Street analysts.

How has Quest Diagnostics' stock performed in 2022?

Quest Diagnostics' stock was trading at $173.01 at the beginning of 2022. Since then, DGX shares have decreased by 18.9% and is now trading at $140.32.
View the best growth stocks for 2022 here
.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, October 20th 2022.
View our DGX earnings forecast
.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) announced its earnings results on Thursday, July, 21st. The medical research company reported $2.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.10. The medical research company earned $2.45 billion during the quarter, compared to the consensus estimate of $2.34 billion. Quest Diagnostics had a trailing twelve-month return on equity of 24.62% and a net margin of 14.02%. The firm's revenue was down 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.18 earnings per share.
Read the conference call transcript
.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Tuesday, May 17th. Shareholders of record on Wednesday, July 6th will be given a dividend of $0.66 per share on Wednesday, July 20th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.88%. The ex-dividend date is Tuesday, July 5th.
Read our dividend analysis for DGX
.

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics (NYSE:DGX) pays an annual dividend of $2.64 per share and currently has a dividend yield of 1.89%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 21.96%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DGX will have a dividend payout ratio of 31.69% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DGX.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics announced that its Board of Directors has approved a share buyback plan on Thursday, February 4th 2021, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 6.1% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board of directors believes its shares are undervalued.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY 2022 earnings guidance on Friday, July, 29th. The company provided earnings per share (EPS) guidance of $9.55-$9.95 for the period, compared to the consensus earnings per share estimate of $9.33. The company issued revenue guidance of $9.50 billion-$9.75 billion, compared to the consensus revenue estimate of $9.42 billion.

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include Victory Capital Management Inc. (2.58%), Robeco Institutional Asset Management B.V. (0.75%), Sumitomo Mitsui Trust Holdings Inc. (0.51%), DekaBank Deutsche Girozentrale (0.41%), AustralianSuper Pty Ltd (0.23%) and Wedge Capital Management L L P NC (0.23%). Insiders that own company stock include Catherine T Doherty, Daniel Stanzione, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe, Stephen H Rusckowski, Stephen H Rusckowski and Timothy M Ring.
View institutional ownership trends
.

How do I buy shares of Quest Diagnostics?

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $140.32.

How much money does Quest Diagnostics make?

Quest Diagnostics (NYSE:DGX) has a market capitalization of $16.36 billion and generates $10.79 billion in revenue each year. The medical research company earns $2.00 billion in net income (profit) each year or $12.02 on an earnings per share basis.

How many employees does Quest Diagnostics have?

Quest Diagnostics employs 49,000 workers across the globe.

Does Quest Diagnostics have any subsidiaries?

The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).
Read More

When was Quest Diagnostics founded?

Quest Diagnostics was founded in 1967.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07094. The official website for the company is www.questdiagnostics.com. The medical research company can be reached via phone at (973) 520-2700, via email at investor@questdiagnostics.com, or via fax at 201-462-4169.

This page (NYSE:DGX) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.